Cover Image
市場調查報告書

類鼻疽感染疾病 : 開發中產品分析

Burkholderia Infections - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 293881
出版日期 內容資訊 英文 75 Pages
訂單完成後即時交付
價格
Back to Top
類鼻疽感染疾病 : 開發中產品分析 Burkholderia Infections - Pipeline Review, H2 2016
出版日期: 2016年12月30日 內容資訊: 英文 75 Pages
簡介

類鼻疽感染疾病是由類鼻疽溶鈣磷細菌所引起的感染疾病,症狀的發展有從低燒開始的肺炎、咳嗽、充血、呼吸急促、喘鳴。發病要素為免疫系統衰弱和肺部疾病,治療則使用抗生劑。

本報告提供類鼻疽感染疾病治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

類鼻疽感染疾病概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • Arno Therapeutics, Inc.
  • Bavarian Nordic A/S
  • Emergent BioSolutions Inc.
  • Eumedica SA
  • Grifols, S.A.
  • NanoBio Corporation
  • Sarepta Therapeutics, Inc.
  • Soligenix, Inc.
  • Syntiron LLC
  • TGV-Laboratories
  • Vault Pharma Inc.

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 關註資訊和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8856IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia Infections - Pipeline Review, H2 2016, provides an overview of the Burkholderia Infections (Infectious Disease) pipeline landscape.

Burkholderia infections are caused by Burkholderia cepacia bacteria. Symptoms include low-grade fever, progressing to much more serious conditions, including pneumonia, cough, congestion, shortness of breath, and wheezing. Predisposing factors include weakened immune system and lung diseases. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burkholderia Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Burkholderia Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burkholderia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Burkholderia Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Burkholderia Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Burkholderia Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Burkholderia Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Burkholderia Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Burkholderia Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Burkholderia Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Burkholderia Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Burkholderia Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Burkholderia Infections Overview
  • Therapeutics Development
    • Pipeline Products for Burkholderia Infections - Overview
    • Pipeline Products for Burkholderia Infections - Comparative Analysis
  • Burkholderia Infections - Therapeutics under Development by Companies
  • Burkholderia Infections - Therapeutics under Investigation by Universities/Institutes
  • Burkholderia Infections - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Burkholderia Infections - Products under Development by Companies
  • Burkholderia Infections - Products under Investigation by Universities/Institutes
  • Burkholderia Infections - Companies Involved in Therapeutics Development
    • Aridis Pharmaceuticals LLC
    • Arno Therapeutics Inc
    • Bavarian Nordic A/S
    • Emergent BioSolutions Inc
    • Eumedica SA
    • Grifols SA
    • Sarepta Therapeutics Inc
    • Soligenix Inc
    • Syntiron LLC
    • TGV-Laboratories
    • Vault Pharma Inc
  • Burkholderia Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antisense Oligonucleotide to Inhibit AcpP for Burkholderia Cepacia Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotide to Inhibit Nucleoporin p62 for Burkholderia Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AR-13 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARD-3100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARD-3150 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Burkholderia pseudomallei vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Burkholderia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Burkholderia vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dusquetide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EV-035 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GC-072 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melioidosis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Mul-1867 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Panaecin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SGX-943 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • temocillin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VPI-231 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Burkholderia Infections - Dormant Projects
  • Burkholderia Infections - Discontinued Products
  • Burkholderia Infections - Product Development Milestones
    • Featured News & Press Releases
      • May 31, 2016: FDA Grants Soligenix "Fast Track" Designation for SGX943 for the Treatment of Melioidosis
      • Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
      • Aug 14, 2014: US DTRA to fund preclinical work on Evolva's antibiotic GC-072
      • Feb 21, 2014: Bavarian Nordic's MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development
      • Feb 21, 2014: Bavarian Nordic's MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development
      • Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
      • Sep 10, 2012: Evolva Presents Preclinical Data On EV-035 At ICAAC
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Burkholderia Infections, H2 2016
  • Number of Products under Development for Burkholderia Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Burkholderia Infections - Pipeline by Aridis Pharmaceuticals LLC, H2 2016
  • Burkholderia Infections - Pipeline by Arno Therapeutics Inc, H2 2016
  • Burkholderia Infections - Pipeline by Bavarian Nordic A/S, H2 2016
  • Burkholderia Infections - Pipeline by Emergent BioSolutions Inc, H2 2016
  • Burkholderia Infections - Pipeline by Eumedica SA, H2 2016
  • Burkholderia Infections - Pipeline by Grifols SA, H2 2016
  • Burkholderia Infections - Pipeline by Sarepta Therapeutics Inc, H2 2016
  • Burkholderia Infections - Pipeline by Soligenix Inc, H2 2016
  • Burkholderia Infections - Pipeline by Syntiron LLC, H2 2016
  • Burkholderia Infections - Pipeline by TGV-Laboratories, H2 2016
  • Burkholderia Infections - Pipeline by Vault Pharma Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Burkholderia Infections - Dormant Projects, H2 2016
  • Burkholderia Infections - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Burkholderia Infections, H2 2016
  • Number of Products under Development for Burkholderia Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top